Study Results Demonstrate Ability of T-SPOT®.TB to Monitor Declining Response in Subjects Receiving Anti-TB Treatment Oxford Immunotec Completes $40M Financing Study Results Confirm T-SPOT®.TB is Cost-Effective in TB Control Programmes Study Results Suggest the Utility of T-SPOT®.TB in Monitoring Treatment for Latent TB Infection (LTBI) Report Highlights the Reliability of T-SPOT®.TB Following Administration of the Tuberculin Skin Test Oxford Immunotec Ltd Wins Best Healthcare Innovation Award and Recieves the Additional Accolade of Overall Winner of the Martin and Audrey Wood Enterprise Awards 2007 Study Results Confirm Utility of T-SPOT®.TB as a Rapid Rule Out Test for Tuberculosis Disease Oxford Immunotec Grants License Over T-SPOT® Technology to Sanofi Pasteur for Human Vaccine Research Study Results Confirm Superior Efficacy of T-SPOT®.TB Over QuantiFERON and the TST in Detecting TB Infection in HIV Patients Oxford Immunotec Announces Appointment of President – North America and Filing for FDA Approval for T-SPOT®.TB Study Results Support Use of T-SPOT®.TB to Monitor Latent TB Infection Study Results Confirm Superior Performance of Oxford Immunotec Ltd's T-SPOT®.TB Over Other Diagnostic Tests for Tuberculosis Oxford Immunotec Strengthens Team with Two Strategic Board Appointments Oxford Immunotec Sponsors Doctors.net.uk and Masterclass Plus Healthcare Training Programmes to Support Best Practice Guidelines for the Diagnosis of TB Study Results Confirm Ability Of T-SPOT®.TB to Detect Tuberculosis Disease in HIV Infected Patients 42 Articles